RESUMEN

BACKGROUND: De novo atrial fibrillation (AF) is rare in pregnancy. The exact pathophysiology of AF is unclear; it might be caused by several cardiovascular and hemodynamic changes that occur in pregnancy, leading to an increased stretch in myocardial cells of the atrial wall. CASE DESCRIPTION: A 26-year-old primigravida with a thus far uncomplicated pregnancy presents with symptoms of heart palpitations, shortness of breath and chest pain. The CTG was normal but an ECG showed de novo atrial fibrillation. The patient was given two doses of digoxin 0.25mg after which sinus rhythm was achieved. No anatomical substrate was found; hence it was seen as most likely caused by increased hemodynamic demands in pregnancy. The delivery and postpartum period were uncomplicated. CONCLUSION: AF is rarely seen in pregnancy. Treatment favours rate and/or rhythm control with metoprolol and digoxin, respectively. Anticoagulation is not indicated in lone AF during pregnancy. Vaginal birth is preferred.

Asunto(s)

Fibrilación Atrial , Femenino , Embarazo , Humanos , Adulto , Fibrilación Atrial/diagnóstico , Fibrilación Atrial/tratamiento farmacológico , Mujeres Embarazadas , Metoprolol/uso terapéutico , Atrios Cardíacos , Digoxina/uso terapéutico , Antiarrítmicos/uso terapéutico

RESUMEN

BACKGROUND: Patients with acute-onset symptomatic atrial fibrillation (AF) can be treated with flecainide. However, flecainide may induce arrhythmias and/or exaggerate heart failure. Therefore, validated markers to predict the efficacy of flecainide and prevent adverse effects are required. We hypothesised that lower NT-proBNP plasma levels correlate with higher success rates of cardioversion with flecainide in patients with AF. METHODS: In this prospective single-centre study, we included 112 subsequent patients with acute-onset (< 24 h) symptomatic AF. Patients with symptoms of heart failure and ECG signs of ischaemia were excluded. Baseline laboratory measurements, including NT-proBNP, were done. Echocardiograms were performed ~ 2 weeks after restoration of SR. RESULTS: Cardioversion with flecainide was successful in 91 patients (87 %). NT-proBNP was lower in patients with successful cardioversion (P < 0.001). Logistic regression indicated NT-proBNP as an independent predictor of successful cardioversion. A cut-off NT-proBNP value of 1550 pg/ml provided optimal test accuracy to predict successful cardioversion. CONCLUSION: In patients with < 24 h of symptomatic AF, NT-proBNP levels up to 1550 pg/ml correlate with high success rates (94 %) of cardioversion with flecainide. Conversely, NT-proBNP higher than 1550 pg/ml correlates with poor success rates (36 %). Further research is needed to validate the predictive value of NT-proBNP for successful cardioversion with flecainide.